NUREXONE BIOLOGIC INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.58 CAD | -7.94% |
|
-7.94% | +96.61% |
| Apr. 25 | NurExone Biologic Announces OTCQB Listing And DTC Eligibility | MT |
| Apr. 02 | NurExone Biologic Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 27.77M 38.26M |
|---|---|---|---|---|---|
| Net income 2024 * | -4M -5.51M | Net income 2025 * | -4M -5.51M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-4.69
x | P/E ratio 2025 * |
-4.69
x | Employees | 12 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.95% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -7.94% | ||
| 1 week | -7.94% | ||
| Current month | -24.68% | ||
| 1 month | -25.64% | ||
| 3 months | +68.12% | ||
| 6 months | +84.13% | ||
| Current year | +96.61% |
1 week
0.58
0.65
1 month
0.570.78
Current year
0.261.19
1 year
0.191.19
3 years
0.101.19
5 years
0.101.19
10 years
0.101.19
| Managers | Title | Age | Since |
|---|---|---|---|
Lior Shaltiel
CEO | Chief Executive Officer | - | 21-03-31 |
Eran Ovadya
DFI | Director of Finance/CFO | - | 22-06-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jay Richardson
BRD | Director/Board Member | 78 | 22-01-02 |
Gadi Riesenfeld
BRD | Director/Board Member | 79 | 23-07-05 |
Yoram Drucker
CHM | Chairman | 59 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 0.58 | -7.94% | 86,632 |
| 24-04-29 | 0.63 | -3.08% | 6,650 |
| 24-04-26 | 0.65 | -.--% | 81,350 |
| 24-04-25 | 0.65 | +3.17% | 16,900 |
| 24-04-24 | 0.63 | -3.08% | 15,850 |
Delayed Quote Toronto S.E., April 30, 2024 at 03:53 pm EDT
More quotes
NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.
Calendar
2024-05-21
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.422
USD
Average target price
2.907
USD
Spread / Average Target
+588.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +96.61% | 27.77M | |
| +0.17% | 42.19B | |
| +10.92% | 42.24B | |
| +44.30% | 40.15B | |
| -6.20% | 28.31B | |
| +5.23% | 24.63B | |
| -24.79% | 18.2B | |
| +26.69% | 12.01B | |
| -3.13% | 11.76B | |
| +6.57% | 10.4B |
- Stock Market
- Equities
- NRX Stock
